Nectero Medical

Nectero Medical focuses on the development of the disruptive early-stage treatment of abdominal aortic aneurysms (AAA). Nectero has developed a patented compound that stabilizes elastin and improves tissue strength that can be used as early treatment for patients living with AAA. Nectero’s potential customers include the currently diagnosed and undiagnosed 1 million people in the US living with AAA. The US only represents 25.6 percent of the worlds AAA market.